US 12,577,551 B2Granted

Method of purifying botulinum toxin

AssigneeJetema Co., Ltd.

InventorsJae Young Kim, Jeong Sun Nam, Seungho Kim, Seung Kwan Choi, Hyun Taek Lim, Jin Hee Choi

Life of this patent

Estimating the term…

Abstract

Disclosed is a method of purifying a botulinum toxin comprising (a) pre-treating a culture solution containing a botulinum toxin, (b) purifying the pre-treated botulinum toxin using cation exchange chromatography, (c) purifying the botulinum toxin using hydrophobic chromatography, and (d) purifying the botulinum toxin using anion exchange chromatography. The method is capable of purifying a botulinum toxin with high purity and activity and is thus useful for botulinum toxin production.

Claims8

Dependent claims

A method of purifying a 900 kDa botulinum toxin complex, comprising:

(a) pre-treating a culture solution containing a botulinum toxin;
(b) applying the pre-treated botulinum toxin from step (a) to cation exchange chromatography using an SP column to bind the botulinum toxin to the cation exchange chromatography medium, and separating the botulinum toxin which is bound to the cation exchange chromatography medium, to obtain a botulinum toxin-containing solution;
(c) applying the botulinum toxin-containing solution obtained in step (b) to hydrophobic chromatography using a phenyl column to obtain a botulinum toxin-containing solution;
and
(d) applying the botulinum toxin-containing solution obtained in step (c) to anion exchange chromatography using a Q column to bind the botulinum toxin to the anion exchange chromatography medium, and separating the 900 kDa botulinum toxin complex which is bound to the anion exchange chromatography medium, to purify the botulinum toxin,
wherein the SP column is selected from the group consisting of (i) a column containing a resin containing a sulfopropyl functional group, having a 6% spherical, cross-linked agarose matrix form, and having a DBC of 55 mg/mL based on ribonuclease A and a particle size of 34 μm, (ii) an SP FF (fast flow) column, and (iii) a column containing a cation exchange resin comprising an agarose matrix and a sulfonate cation exchanger coupled to the agarose matrix;
wherein the phenyl column is selected from the group consisting of (i) a column containing a resin having a cross-linked agarose 6% matrix form, a degree of substitution of 25 μmol phenyl groups/mL, and a bead size of 34 μm, (ii) a phenyl FF (Fast Flow) column, and (iii) a column containing a hydrophobic chromatography resin comprising a cross-linked agarose matrix and phenyl group ligands;
and
wherein the Q column is selected from the group consisting of (i) a column containing an anion resin comprising an agarose matrix and quaternary amine functional groups CH2CH2CH2SO3, (ii) a column containing a resin containing a methacrylic bead with a particle size of 65 μm comprising a quaternary ammonium (Q) functional group, (iii) a Q FF column, and a Q HP column.

6 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

A method of purifying a 900 kDa botulinum toxin complex, comprising:

(a) pre-treating a culture solution containing a botulinum toxin;
(b) applying the pre-treated botulinum toxin from step (a) to cation exchange chromatography using an SP column to bind the botulinum toxin to the cation exchange chromatography medium, and separating the botulinum toxin which is bound to the cation exchange chromatography medium, to obtain a botulinum toxin-containing solution;
(c) applying the botulinum toxin-containing solution obtained in step (b) to hydrophobic chromatography using a phenyl column to obtain a botulinum toxin-containing solution;
and
(d) applying the botulinum toxin-containing solution obtained in step (c) to anion exchange chromatography using a Q column to bind the botulinum toxin to the anion exchange chromatography medium, and separating the 900 kDa botulinum toxin complex which is bound to the anion exchange chromatography medium, to purify the botulinum toxin,
wherein the SP column is selected from the group consisting of (i) a column containing a resin containing a sulfopropyl functional group, having a 6% spherical, cross-linked agarose matrix form, and having a DBC of 55 mg/mL based on ribonuclease A and a particle size of 34 μm, (ii) an SP FF (fast flow) column, and (iii) a column containing a cation exchange resin comprising an agarose matrix and a sulfonate cation exchanger coupled to the agarose matrix;
wherein the phenyl column is selected from the group consisting of (i) a column containing a resin having a cross-linked agarose 6% matrix form, a degree of substitution of 25 μmol phenyl groups/mL, and a bead size of 34 μm, (ii) a phenyl FF (Fast Flow) column, and (iii) a column containing a hydrophobic chromatography resin comprising a cross-linked agarose matrix and phenyl group ligands;
and
wherein the Q column is selected from the group consisting of (i) a column containing an anion resin comprising an agarose matrix and quaternary amine functional groups CH2CH2CH2SO3, (ii) a column containing a resin containing a methacrylic bead with a particle size of 65 μm comprising a quaternary ammonium (Q) functional group, (iii) a Q FF column, and a Q HP column.

6 more elements